Evaluation of Immune Function in Biliary Atresia Children With Prolonged Jaundice

Impaired T-Lymphocyte Proliferative Function in Biliary Atresia Children With Prolonged Jaundice

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00155194

Enrollment

Registered

2005-09-12

Start date

2004-04-30

Completion date

Unknown

Last updated

2005-09-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Biliary Atresia

Brief summary

Null hypothesis of this study: Biliary atresia patients with cholestatic jaundice do not have systemic immunity defect.

Detailed description

Biliary atresia patients with cholestatic jaundice were noted to have increased incidence of infectious complications. Previous animal models of bile duct ligation with acute jaundice ever demonstrated impairment of both humoral and cellular immune function. We performed the immunity study in biliary atresia patients due to the lack of comprehensive systemic immunity study in pediatric cholestatic model. Systemic humoral immunity (total serum IgG, IgA, IgM, C3 and C4), specific cellular immunity (lymphocyte classification, mitogen response, cytokines level after PHA stimulation test), and non-specific cellular immunity (absolute neutrophil count, PMN CD11b/CD18 expression level, PMN superoxide release function, and PMN phagocytosis function) were tested. Association with serum bilirubin level, nutritional status and blood biochemical values were tested to see the relation between systemic immune function and cholestatic jaundice.

Interventions

None listed

Study design

Observational model

DEFINED_POPULATION

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

1 Years to No maximum

Healthy volunteers

Inclusion criteria

Biliary patients older than 1-year-old status post Kasai operation.

Exclusion criteria

Received liver transplantation, immunosuppresant, systemic immunoglobulin (within 6 months) and obvious infectious episode (within 2 weeks).

Countries

Taiwan

Contacts

Primary ContactJia-Feng Wu, MD

water@ha.mc.ntu.edu.tw886-2-23123456

Outcome results